European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading

MT Newswires Live
04 Mar

European equities traded in the US as American depositary receipts kicked off the week on strong note late Monday morning, surging 1.83% higher to 1,442.61 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and biopharmaceutical company Genfit (GNFT), which rose 6.3% and 6% respectively. They were followed by accommodations booking site trivago (TRVG) and financial services company ING Groep (ING), which increased 5.6% and 5.3% respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm Evaxion Biotech (EVAX), which dropped 8.5% and 6.7% respectively. They were followed by internet browser company Opera (OPRA) and semiconductor company Sequans Communications (SQNS), which were down 2% and 1.7% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Biodexa Pharmaceuticals (BDRX), which advanced 6.3% and 3.7% respectively. They were followed by biopharmaceutical company TC Biopharm (TCBP) and mining company BHP Group (BHP), which were up 3.6% and 3.1% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Bicycle Therapeutics (BCYC), which fell 4% and 2.4% respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and Verona Pharma (VRNA), which lost 2.1% and 1.6% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10